[Valsartan improves symptoms and quality of life in patients with chronic heart failure]

Related Experiment Videos

M Baumhäkel1, U Müller, M Böhm

  • 1Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg/Saar.

MMW Fortschritte Der Medizin
|June 11, 2008
PubMed

Insights

Outpatient treatment with valsartan effectively improved chronic heart failure symptoms and quality of life. This guideline-adherent therapy demonstrated significant benefits with a low incidence of adverse events.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure (CHF) management requires effective therapeutic strategies.
  • Angiotensin-receptor blockers (ARBs) are key in guideline-recommended CHF treatment.
  • Valsartan is an ARB used for heart failure management.

Purpose of the Study:

  • To evaluate the efficacy of outpatient treatment with valsartan for chronic heart failure.
  • To assess adherence to guideline recommendations in CHF management with valsartan.
  • To determine the impact of valsartan on patient outcomes in an outpatient setting.

Main Methods:

  • Prospective, open-label, multicenter trial in Germany.
  • 1863 consecutive patients with CHF treated by 829 physicians.
  • Evaluation of NYHA classification, quality of life, blood pressure, and adverse events over 12 weeks.

Main Results:

  • Significant improvements in NYHA classification and quality of life observed.
  • Reduced systolic and diastolic blood pressure noted, dose-dependent.
  • Low incidence of adverse events (0.2%).

Conclusions:

  • Guideline-recommended outpatient treatment with valsartan improves CHF symptoms.
  • Results align with previous randomized controlled trials.
  • Valsartan is effective and well-tolerated in an outpatient CHF setting.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.